A Drug Interaction Study of Clarithromycin and LY3502970 in Healthy Participants

NCT05469126 · Completed

Last updated 2026-05-28

This clinical trial tests how the antibiotic clarithromycin affects the levels of the experimental drug LY3502970 in the bloodstream of healthy volunteers.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Non-randomized, open-label (no blinding) basic-science study

Participants 26 people

Who can join Ages 21–70 · all sexes Healthy volunteers accepted.

Timeline Started 2022-08 · est. completion 2022-11

Where 1 site · Singapore

What this study is testing ClinicalTrials.gov NCT05469126 ↗

Description as written by the study sponsor.

The main purpose of this study is to determine the levels of study drug called LY3502970 in the blood stream when administered alone and in combination with clarithromycin in healthy participants. This study will last up to approximately 85 days for each participant.

Treatments tested

LY3502970 Drug

Administered orally.
Clarithromycin Drug

Administered orally.

Main thing measured	Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) From Time Zero to Infinity AUC(0-∞) of LY3502970
Sponsor	Eli Lilly and Company
Conditions studied	Healthy
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05469126 ↗